Kezar Life Sciences (NASDAQ:KZR) Upgraded at Wall Street Zen

Kezar Life Sciences (NASDAQ:KZR) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a research note on Wednesday, July 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.00.

Kezar Life Sciences Trading Down 0.8%

Shares of KZR opened at $3.95 on Friday. Kezar Life Sciences has a one year low of $3.62 and a one year high of $9.18. The stock has a 50-day moving average price of $4.15 and a 200 day moving average price of $4.48. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.29 and a current ratio of 7.29. The company has a market capitalization of $28.93 million, a P/E ratio of -0.41 and a beta of 0.61.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $0.28. Sell-side analysts forecast that Kezar Life Sciences will post -4.39 EPS for the current fiscal year.

Institutional Trading of Kezar Life Sciences

Institutional investors have recently added to or reduced their stakes in the business. BML Capital Management LLC lifted its position in shares of Kezar Life Sciences by 738.6% in the 1st quarter. BML Capital Management LLC now owns 408,138 shares of the company’s stock worth $1,992,000 after buying an additional 359,470 shares during the last quarter. Stonepine Capital Management LLC raised its stake in Kezar Life Sciences by 69.9% during the second quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock worth $778,000 after acquiring an additional 69,859 shares during the period. Shay Capital LLC bought a new position in Kezar Life Sciences in the fourth quarter worth about $398,000. Dimensional Fund Advisors LP acquired a new position in Kezar Life Sciences in the fourth quarter valued at approximately $217,000. Finally, Woodline Partners LP acquired a new position in Kezar Life Sciences in the first quarter valued at approximately $125,000. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.